INTEGRILINÂ® (eptifibatide) Injection Clinical Support Slide Lecture ...

More documents

Recommendations

Info

SUMMARY of 2011 ACC/AHA focused Update of the 2007Guidelines for UA/NSTEMIClass I: Benefits >>>> Risk (Should be given)‣ If initial INVASIVE strategy is selected then dual-antiplatelet therapy isrecommended on presentation• Before PCI:• ASA + Clopidogrel (Level B)• ASA + An IV GP IIb/IIIa inhibitor (Level A)• At the time of PCI• ASA + Clopidogrel (if not started) (Level A)• ASA + Prasugrel (Level B)• ASA + An IV GP IIb/IIIa inhibitor (Level A)‣ If initial CONSERVATIVE strategy is selected and diagnostic angiography isrecommended• Upstream Clopidogrel + ASA + anticoagulant therapy (Level B)• Upstream IV GP IIb/IIIa inhibitor + ASA + anticagulant therapy (Level A)
SUMMARY of 2011 ACC/AHA focused Update of the 2007Guidelines for UA/NSTEMIClass IIa: Benefit > Risk (Reasonable to give)‣ If PCI has been selected as a post-angiography management strategy• Administer an IV GP IIb/IIIa inhibitor, if not started before the diagnostic angiography(particularly for trponin-positive and/or other high risk patients) (Level A)‣ If in initial conservative strategy, recurrent ischemic discomfort persisits withclopidogrel, ASA, and anticoagulant therapy• Add IV GP IIb/IIIa inhibitor before diagnostic angiography (Level C)Class IIb Benefit ≥ Risk (May be considered)‣ For high ischemic risk + low bleeding risk patients, If an invasive strategy isselected• The Upstream use of GP IIb/IIIa inhibitor (Level B)Class III: No benefit‣ Low ischemic risk / high bleeding risk on ASA + clopidogrel• Upstream GP IIb/IIIa inhibitors are not recommended (Level B)
Page 1 and 2: .An Update onINTEGRILIN ® (eptifib
Page 3: Thrombus and Microemboli:The heart
Page 9 and 10: MI Ratepursuit6%4%Early Use of Epti
Page 11 and 12: pursuitMI Prior to PCI% Mortality a
Page 13 and 14: Baseline Inhibition (%)Inhibition o
Page 15 and 16: Death or MI* at 30 Days With Eptifi
Page 17 and 18: Death, MI, UTVR, or TBO at30 Days b
Page 19 and 20: EVA-AMI: Eptifibatide Equal to Abci
Page 21 and 22: The FATA trial ( Facilitated Angiop
Page 24 and 25: Figure 1. Percent inhibition of pla
Page 26 and 27: Figure 3. Percent platelet GP IIb/I
Page 28 and 29: Figure 5. The pre-PCI cTFC and post
Page 30 and 31: A Well-Established Safety Profile
Page 32 and 33: Major and Minor TIMI Bleeding Durin
Page 34 and 35: Clinical Implications• Early use
Page 36 and 37: INTEGRILIN ® (eptifibatide) Inject
Page 42 and 43: Dosing Label Change forPatients wit
Page 44 and 45: INTEGRILIN TM (eptifibatide) Inject
Page 50 and 51: Following ACC/AHA Guidelines Signif
Page 52: Eptifibatide: backed by evidence in

INTEGRILINÂ® (eptifibatide) Injection Clinical Support Slide Lecture ...

Create successful ePaper yourself

Delete template?

Save as template?